Device Trial Radar · NCT07428356
Histotripsy for Ablation of Liver Tumours in Asia
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 7, 2025
Primary completion
Nov 7, 2027
Study completion May 7, 2029
Sponsor
- Lead sponsor
- National Cancer Centre, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.
Conditions
- Liver Malignant Tumors
Interventions
Histotripsy using HistoSonics Edison™ SystemDevice
The histotripsy procedure will be performed using the HistoSonics Edison™ System, an image-guided, non-invasive focused ultrasound platform specifically designed for mechanical tissue fractionation. Key steps include general anaesthesia and positioning, pre-treatment planning and imaging, and histotripsy ablation procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-month local control rate.Time frame: 6 months post-procedure.
- Major complication rate.Time frame: 30 days post-procedure.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
National University Hospital
Singapore, Singapore · Recruiting
National Cancer Centre Singapore
Singapore, Singapore · Recruiting
Singapore General Hospital
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.